CoChat

Why paracetamol (acetaminophen) is a suitable first choice for treating mild to moderate acute pain in adults with liver, kidney or cardiovascular disease, gastrointestinal disorders, asthma, or who are older

Open access
Alchin, John, Dhar, Arti, Siddiqui, Kamran, Christo, Paul J. · 2022 · Current Medical Research and Opinion

The DOI matches its Crossref record; 125 of the 125 references it cites were found in a registry or an index.

Abstract

Acute pain is among the most common reasons that people consult primary care physicians, who must weigh benefits versus risks of analgesics use for each patient. Paracetamol (acetaminophen) is a first-choice analgesic for many adults with mild to moderate acute pain, is generally well tolerated at recommended doses (≤4 g/day) in healthy adults and may be preferable to non-steroidal anti-inflammatory drugs that are associated with undesirable gastrointestinal, renal, and cardiovascular effects. Although paracetamol is widely used, many patients and physicians still have questions about its suitability and dosing, especially for older people or adults with underlying comorbidities, for whom there are limited clinical data or evidence-based guidelines. Inappropriate use may increase the risks of both overdosing and inadequate analgesia. To address knowledge deficits and augment existing guidance in salient areas of uncertainty, we have researched, reviewed, and collated published evidence and expert opinion relevant to the acute use of paracetamol by adults with liver, kidney, or cardiovascular diseases, gastrointestinal disorders, asthma, or/and who are older. A concern is hepatotoxicity, but this is rare among adults who use paracetamol as directed, including people with cirrhotic liver disease. Putative epidemiologic associations of paracetamol use with kidney or cardiovascular disease, hypertension, gastrointestinal disorders, and asthma largely reflect confounding biases and are of doubtful relevance to short-term use (<14 days). Paracetamol is a suitable first-line analgesic for mild to moderate acute pain in many adults with liver, kidney or cardiovascular disease, gastrointestinal disorders, asthma, and/or who are older. No evidence supports routine dose reduction for older people. Rather, dosing for adults who are older and/or have decompensated cirrhosis, advanced kidney failure, or analgesic-induced asthma that is known to be cross-sensitive to paracetamol, should be individualized in consultation with their physician, who may recommend a lower effective dose appropriate to the circumstances.

Overview

Integrity signals

Registry

Crossref · 10.1080/03007995.2022.2049551

Cites

125 of 125 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

The text we found for this paper looks like another document, so its claims and self-check weren’t run. The registry and citation checks still apply.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The text we found for this paper looks like another document, so the self-check wasn’t run.

Citations

Cites

Show all 125 references

Research works printed but not linked: 7

  1. Jóźwiak-Bębenista M, 2014, Acta Pol Pharm, 71, 11
  2. Hunt RH, 2007, Can Fam Physician, 53, 1177
  3. Pavličević I, 2008, Can J Clin Pharmacol, 15, e372–382
  4. Wójcicki J, 1984, Pol J Pharmacol Pharm, 36, 59
  5. Kaas Oldenburg LI, 2020, J Pharm (Cairo), 2020, 1354209
  6. Bannwarth B, 2001, J Rheumatol, 28, 182
  7. Foster J, 2016, Front Pharmacol, 7, 54

Cited by

See all 65

Metadata

Authors
Alchin, J., Dhar, A., Siddiqui, K., & Christo, P. J.
Affiliations
  • Burwood Hospital (NZ)
  • GlaxoSmithKline Consumer Healthcare Pte Ltd (Singapore) (SG)
  • Johns Hopkins University (US)
Corresponding author
Dhar, Arti
Venue
Current Medical Research and Opinion
Published
2022-03-29
Volume
38
Issue
5
Pages
811-825
ISSN
  • 0300-7995 (ISSN-L)
  • 1473-4877
OpenAlex
W4220690142
Cited by
65
References
125
Citations by year
2026: 11 · 2025: 15 · 2024: 21 · 2023: 13 · 2022: 5
FWCI
3.72
Type
journal article
Language
en
Open access
Locations
  • Current Medical Research and Opinion (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Funders
GlaxoSmithKline Consumer Healthcare
Topics
  • Health Sciences › Medicine › Anesthesiology and Pain Medicine › Pain Management and Opioid Use
  • Health Sciences › Medicine › Anesthesiology and Pain Medicine › Anesthesia and Pain Management
  • Health Sciences › Medicine › Pharmacology (medical) › Inflammatory mediators and NSAID effects
Keywords
paracetamol, acute pain, analgesic dosing, older adults, liver disease, liver cirrhosis, kidney disease, cardiovascular disease, gastrointestinal diseases, asthma, hepatotoxicity, dose reduction, comorbidities, primary care
MeSH terms
Acetaminophen, Adult, Aged, Analgesics, Asthma, Cardiovascular Diseases, Gastrointestinal Diseases, Humans, Kidney, Liver, Analgesics, Non-Narcotic, Acute Pain

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Why paracetamol (acetaminophen) is a suitable first choice for treating mild to moderate acute pain in adults with liver, kidney or cardiovascular disease, gastrointestinal disorders, asthma, or who are older. https://app.cochat.ai/papers/10.1080/03007995.2022.2049551
The paper
Alchin, J., Dhar, A., Siddiqui, K., & Christo, P. J. (2022). Why paracetamol (acetaminophen) is a suitable first choice for treating mild to moderate acute pain in adults with liver, kidney or cardiovascular disease, gastrointestinal disorders, asthma, or who are older. Current Medical Research and Opinion. https://doi.org/10.1080/03007995.2022.2049551

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.